{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T21:54:32Z","timestamp":1777586072432,"version":"3.51.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP25fk0210174"],"award-info":[{"award-number":["JP25fk0210174"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Direct-acting antivirals (DAAs) achieve high sustained virologic response (SVR) rates in patients with hepatitis C virus (HCV) infection. However, the long-term prognosis and cause-specific mortality post-SVR remain unclear. This study analyzed 1753 HCV-infected patients without a history of hepatocellular carcinoma treatment who achieved SVR with DAAs and did not develop cancer. Liver disease-related (LDR) and non-LDR mortalities were assessed using age- and sex-adjusted standardized mortality ratios (SMRs) compared with the general population. During a mean follow-up of 59.2\u00a0months, 122 patients died. The SMR for all-cause mortality was 1.050 (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.588). The SMRs for LDR and non-LDR mortalities were 7.819 (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001) and 0.566 (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001), respectively. The SMR for extrahepatic malignancy-related mortality was significantly lower at 0.593 (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.013), whereas cardiovascular disease (CVD)-related mortality did not differ significantly at 0.884 (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.554). These findings were consistent regardless of age, sex, liver cirrhosis presence, diabetes, or chronic kidney disease. Overall mortality after SVR in patients with HCV was comparable with that of the general population. Nevertheless, LDR mortality remained significantly elevated, whereas non-LDR and extrahepatic malignancy-related mortalities were significantly reduced. These results underscore the importance of continued liver disease surveillance post-SVR, while CVD management should parallel that of the general population.\n                  <\/jats:p>","DOI":"10.1038\/s41598-025-29972-6","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T13:36:04Z","timestamp":1764250564000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cause-specific mortality following sustained virologic response in hepatitis C patients treated with direct-acting antivirals: a standardized mortality ratio analysis"],"prefix":"10.1038","volume":"15","author":[{"given":"Seiichi","family":"Mawatari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiroh","family":"Tanoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kotaro","family":"Kumagai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohei","family":"Oda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ai","family":"Toyodome","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruka","family":"Sakae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunio","family":"Fujisaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukiko","family":"Inada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Uto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Saisyoji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasunari","family":"Hiramine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuaki","family":"Tabu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sho","family":"Ijuin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Hori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsutomu","family":"Tamai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Moriuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuji","family":"Kanmura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akio","family":"Ido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"key":"29972_CR1","unstructured":"World Health Organization. Hepatitis C fact Sheet World Health Organization 2025, https:\/\/www.who.int\/en\/news-room\/fact-sheets\/detail\/hepatitis-c"},{"key":"29972_CR2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad319","author":"D Bhattacharya","year":"2023","unstructured":"Bhattacharya, D., Aronsohn, A., Price, J. & Lo Re, V. Hepatitis C guidance 2023 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Clin. Infect. Dis. https:\/\/doi.org\/10.1093\/cid\/ciad319 (2023).","journal-title":"Clin. Infect. Dis."},{"key":"29972_CR3","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","volume":"73","author":"JM Pawlotsky","year":"2020","unstructured":"Pawlotsky, J. M. et al. EASL recommendations on treatment of hepatitis C: Final update of the series(\u2606). J. Hepatol. 73, 1170\u20131218 (2020).","journal-title":"J. Hepatol."},{"key":"29972_CR4","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/hepr.13474","volume":"50","author":"S Mawatari","year":"2020","unstructured":"Mawatari, S. et al. Viral and host factors are associated with retreatment failure in hepatitis C patients receiving all-oral direct antiviral therapy. Hepatol. Res. 50, 453\u2013465 (2020).","journal-title":"Hepatol. Res."},{"key":"29972_CR5","doi-asserted-by":"publisher","first-page":"16363","DOI":"10.1038\/s41598-024-67169-5","volume":"14","author":"A Toyodome","year":"2024","unstructured":"Toyodome, A. et al. Analysis of the susceptibility of refractory hepatitis C virus resistant to nonstructural 5A inhibitors. Sci. Rep. 14, 16363 (2024).","journal-title":"Sci. Rep."},{"key":"29972_CR6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jhep.2017.08.030","volume":"68","author":"GN Ioannou","year":"2018","unstructured":"Ioannou, G. N., Green, P. K. & Berry, K. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. J. Hepatol. 68, 25\u201332 (2018).","journal-title":"J. Hepatol."},{"key":"29972_CR7","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1053\/j.gastro.2018.07.015","volume":"155","author":"P Nahon","year":"2018","unstructured":"Nahon, P. et al. Incidence of hepatocellular carcinoma after direct antiviral therapy for HCV in patients with cirrhosis included in surveillance programs. Gastroenterology 155, 1436-1450.e1436 (2018).","journal-title":"Gastroenterology"},{"key":"29972_CR8","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/hepr.12393","volume":"45","author":"N Hiramatsu","year":"2015","unstructured":"Hiramatsu, N., Oze, T. & Takehara, T. Suppression of hepatocellular carcinoma development in hepatitis C patients given interferon-based antiviral therapy. Hepatol. Res. 45, 152\u2013161 (2015).","journal-title":"Hepatol. Res."},{"key":"29972_CR9","doi-asserted-by":"publisher","first-page":"e0262267","DOI":"10.1371\/journal.pone.0262267","volume":"17","author":"S Mawatari","year":"2022","unstructured":"Mawatari, S. et al. Features of patients who developed hepatocellular carcinoma after direct-acting antiviral treatment for hepatitis C Virus. PLoS ONE 17, e0262267 (2022).","journal-title":"PLoS ONE"},{"key":"29972_CR10","doi-asserted-by":"publisher","first-page":"ofz185","DOI":"10.1093\/ofid\/ofz185","volume":"6","author":"H Toyoda","year":"2019","unstructured":"Toyoda, H. et al. Trends and efficacy of interferon-free anti-hepatitis C virus therapy in the region of high prevalence of elderly patients, cirrhosis, and hepatocellular carcinoma: A real-world, nationwide, multicenter study of 10 688 patients in Japan. Open Forum Infect. Dis. 6, ofz185 (2019).","journal-title":"Open Forum Infect. Dis."},{"key":"29972_CR11","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1002\/hep.29408","volume":"69","author":"LI Backus","year":"2017","unstructured":"Backus, L. I., Belperio, P. S., Shahoumian, T. A. & Mole, L. A. Impact of sustained virologic response with direct-acting antiviral treatment on mortality in patients with advanced liver disease. Hepatology 69, 487 (2017).","journal-title":"Hepatology"},{"key":"29972_CR12","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1002\/hep.29811","volume":"68","author":"LI Backus","year":"2018","unstructured":"Backus, L. I., Belperio, P. S., Shahoumian, T. A. & Mole, L. A. Direct-acting antiviral sustained virologic response: Impact on mortality in patients without advanced liver disease. Hepatology 68, 827\u2013838 (2018).","journal-title":"Hepatology"},{"key":"29972_CR13","first-page":"3060","volume":"44","author":"T Tada","year":"2024","unstructured":"Tada, T. et al. Viral eradication reduces all-cause mortality in patients with chronic hepatitis C virus infection who had received direct-acting antiviral therapy. Liver Int. Off. J. Int. Assoc. Study Liver 44, 3060\u20133071 (2024).","journal-title":"Liver Int. Off. J. Int. Assoc. Study Liver"},{"key":"29972_CR14","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1093\/cid\/civ396","volume":"61","author":"B Simmons","year":"2015","unstructured":"Simmons, B., Saleem, J., Heath, K., Cooke, G. S. & Hill, A. Long-term treatment outcomes of patients infected with hepatitis C virus: a systematic review and meta-analysis of the survival benefit of achieving a sustained virological response. Clin. Infect. Dis. 61, 730\u2013740 (2015).","journal-title":"Clin. Infect. Dis."},{"key":"29972_CR15","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1053\/j.gastro.2016.09.009","volume":"152","author":"P Nahon","year":"2017","unstructured":"Nahon, P. et al. Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications. Gastroenterology 152, 142-156.e142 (2017).","journal-title":"Gastroenterology"},{"key":"29972_CR16","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.jhep.2018.07.024","volume":"69","author":"GN Ioannou","year":"2018","unstructured":"Ioannou, G. N. et al. Development of models estimating the risk of hepatocellular carcinoma after antiviral treatment for hepatitis C. J Hepatol 69, 1088\u20131098 (2018).","journal-title":"J Hepatol"},{"key":"29972_CR17","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1111\/hepr.13310","volume":"49","author":"R Yamada","year":"2019","unstructured":"Yamada, R. et al. Incidence and risk factors of hepatocellular carcinoma change over time in patients with hepatitis C virus infection who achieved sustained virologic response. Hepatol. Res. 49, 570\u2013578 (2019).","journal-title":"Hepatol. Res."},{"key":"29972_CR18","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.jhep.2024.04.007","volume":"81","author":"T Reiberger","year":"2024","unstructured":"Reiberger, T. et al. EASL position paper on clinical follow-up after HCV cure. J. Hepatol. 81, 326\u2013344 (2024).","journal-title":"J. Hepatol."},{"key":"29972_CR19","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.jhep.2016.01.034","volume":"64","author":"S Bruno","year":"2016","unstructured":"Bruno, S. et al. Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population. J. Hepatol. 64, 1217\u20131223 (2016).","journal-title":"J. Hepatol."},{"key":"29972_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29432","volume":"96","author":"S Miuma","year":"2024","unstructured":"Miuma, S. et al. Non-liver-related mortality in the DAA era: Insights from post-SVR patients with and without previous HCC history. J. Med. Virol. 96, e29432 (2024).","journal-title":"J. Med. Virol."},{"key":"29972_CR21","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jhep.2016.08.004","volume":"66","author":"H Innes","year":"2017","unstructured":"Innes, H. et al. Mortality in hepatitis C patients who achieve a sustained viral response compared to the general population. J. Hepatol. 66, 19\u201327 (2017).","journal-title":"J. Hepatol."},{"key":"29972_CR22","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1007\/s12072-023-10495-z","volume":"17","author":"S Obi","year":"2023","unstructured":"Obi, S. et al. The incidence of all organ malignancies and overall survival of patient with sustained virological response of HCV-comparable to SMR (standardized mortality ratio) of Japan general population. Hep. Intl. 17, 562\u2013572 (2023).","journal-title":"Hep. Intl."},{"key":"29972_CR23","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1111\/jvh.13523","volume":"28","author":"V Calvaruso","year":"2021","unstructured":"Calvaruso, V. et al. Liver and cardiovascular mortality after hepatitis C virus eradication by DAA: Data from RESIST-HCV cohort. J. Viral Hepat. 28, 1190\u20131199 (2021).","journal-title":"J. Viral Hepat."},{"key":"29972_CR24","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1053\/j.gastro.2015.09.007","volume":"150","author":"S Petta","year":"2016","unstructured":"Petta, S. et al. Hepatitis C virus infection is associated with increased cardiovascular mortality: A meta-analysis of observational studies. Gastroenterology 150, 145-155.e144 (2016).","journal-title":"Gastroenterology"},{"key":"29972_CR25","first-page":"448","volume":"39","author":"H Toyoda","year":"2019","unstructured":"Toyoda, H. et al. The impact of HCV eradication by direct-acting antivirals on the transition of precancerous hepatic nodules to HCC: A prospective observational study. Liver Int. Off. J. Int. Assoc. Study Liver 39, 448\u2013454 (2019).","journal-title":"Liver Int. Off. J. Int. Assoc. Study Liver"},{"key":"29972_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0237475","volume":"15","author":"K Tabu","year":"2020","unstructured":"Tabu, K. et al. Hypovascular tumors developed into hepatocellular carcinoma at a high rate despite the elimination of hepatitis C virus by direct-acting antivirals. PLoS ONE 15, e0237475 (2020).","journal-title":"PLoS ONE"},{"key":"29972_CR27","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1053\/j.gastro.2004.11.018","volume":"128","author":"L Cast\u00e9ra","year":"2005","unstructured":"Cast\u00e9ra, L. et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 128, 343\u2013350 (2005).","journal-title":"Gastroenterology"},{"key":"29972_CR28","doi-asserted-by":"crossref","unstructured":"Committee, A. D. A. P. P. 2. Diagnosis and classification of diabetes: Standards of care in diabetes-2024. Diabetes Care 47, S20-s42, (2024).","DOI":"10.2337\/dc24-S002"},{"key":"29972_CR29","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1253\/circj.CJ-23-0285","volume":"88","author":"A Fujiyoshi","year":"2024","unstructured":"Fujiyoshi, A. et al. JCS 2023 guideline on the primary prevention of coronary artery disease. Circ. J. 88, 763\u2013842 (2024).","journal-title":"Circ. J."},{"key":"29972_CR30","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1253\/circj.CJ-22-0794","volume":"87","author":"H Ogino","year":"2023","unstructured":"Ogino, H. et al. JCS\/JSCVS\/JATS\/JSVS 2020 guideline on diagnosis and treatment of aortic aneurysm and aortic dissection. Circ. J. 87, 1410\u20131621 (2023).","journal-title":"Circ. J."},{"key":"29972_CR31","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1177\/17474930221090347","volume":"17","author":"S Miyamoto","year":"2022","unstructured":"Miyamoto, S. et al. Japan stroke society guideline 2021 for the treatment of stroke. Int. J. Stroke 17, 1039\u20131049 (2022).","journal-title":"Int. J. Stroke"},{"key":"29972_CR32","doi-asserted-by":"crossref","unstructured":"Group, K. D. I. G. O. K. C. W. KDIGO 2024 Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 105, S117-s314, (2024).","DOI":"10.1016\/j.kint.2023.10.018"},{"key":"29972_CR33","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo, S. et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53, 982\u2013992 (2009).","journal-title":"Am J Kidney Dis"},{"key":"29972_CR34","unstructured":"Guidelines for the Management of Hepatitis C Virus Infection, http:\/\/www.jsh.or.jp\/medical\/guidelines\/jsh_guidlines\/hepatitis_c"},{"key":"29972_CR35","unstructured":"Statistics of Japan, e-Stat is a portal site for Japanese Government Statistics., https:\/\/www.e-stat.go.jp\/en"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-29972-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-29972-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-29972-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T20:04:06Z","timestamp":1777406646000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-29972-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["29972"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-29972-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7721910\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,27]]},"assertion":[{"value":"26 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"45560"}}